- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01522976
Azacitidina con o senza lenalidomide o vorinostat nel trattamento di pazienti con sindromi mielodisplastiche ad alto rischio o leucemia mielomonocitica cronica
Uno studio randomizzato di fase II/III su azacitidina in combinazione con lenalidomide (NSC-703813) vs. azacitidina da sola vs. azacitidina in combinazione con vorinostat (NSC-701852) per sindromi mielodisplastiche ad alto rischio (MDS) e leucemia mielomonocitica cronica (CMML)
This randomized phase II/III trial studies how well azacitidine works with or without lenalidomide or vorinostat in treating patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, stopping them from dividing, or by stopping them from spreading. Lenalidomide may stop the growth of cancer cells by stopping blood flow to the cancer. Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It is not yet known whether azacitidine is more effective with or without lenalidomide or vorinostat in treating myelodysplastic syndromes or chronic myelomonocytic leukemia.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
PRIMARY OBJECTIVES:
I. To select based on response rate (complete remission, partial remission, or hematologic improvement) either the combination of lenalidomide and azacitidine or the combination of vorinostat and azacitidine for further testing against single-agent azacitidine among patients with higher-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML). (Phase II) II. To compare overall survival between the combination arm selected in the Phase II portion of the trial to single-agent azacitidine among patients with higher-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML). (Phase III)
SECONDARY OBJECTIVES:
I. To estimate relapse-free survival, overall survival and cytogenetic response rate of patients treated on each regimen.
II. To estimate the frequency and severity of toxicities of the three regimens in this patient population.
III. To investigate in a preliminary manner the frequency of subgroups from prestudy cytogenetic studies and correlate these subgroups with clinical outcomes in this patient population.
IV. To collect specimens for banking for use in future research studies.
TERTIARY OBJECTIVES:
I. To evaluate the prevalence of a pre-specified list of molecular lesions (48 total lesions).
II. To assess associations of these lesions with outcomes (response, event-free survival, relapse-free survival, and overall survival).
III. To develop a deoxyribonucleic acid (DNA) methylation biomarker predictive of response to DMTi treatment in MDS.
IV. To harness gene expression profiles as clinical biomarkers of primary resistance to DMTi in MDS.
OUTLINE: Patients are randomized to 1 of 3 treatment arms. In Phase III, patients are randomized to 1 of 2 treatment arms (the combination arm selected in Phase II or the single-agent azacitidine arm).
ARM I: Patients receive azacitidine subcutaneously (SC) or intravenously (IV) on days 1-7 or days 1-5 and 8-9, and lenalidomide orally (PO) once daily (QD) on days 1-21.
ARM II: Patients receive azacitidine as in Arm I.
ARM III: Patients receive azacitidine as in Arm I and vorinostat PO twice daily (BID) on days 3-9.
In all arms, treatment repeats every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for up to 5 years.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 5G2
- Arthur J E Child Comprehensive Cancer Centre
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 3P1
- Clinical Research Unit at Vancouver Coastal Health Authority
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3E 0V9
- CancerCare Manitoba
-
-
New Brunswick
-
Moncton, New Brunswick, Canada, E1C 6Z8
- The Moncton Hospital
-
Saint John, New Brunswick, Canada, E2L 4L2
- Atlantic Health Sciences Corporation-Saint John Regional Hospital
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 2Y9
- QEII Health Sciences Centre/Nova Scotia Health Authority
-
-
Ontario
-
Hamilton, Ontario, Canada, L8V 5C2
- Juravinski Cancer Centre at Hamilton Health Sciences
-
Toronto, Ontario, Canada, M5G 2M9
- University Health Network-Princess Margaret Hospital
-
Toronto, Ontario, Canada, M4N 3M5
- Odette Cancer Centre- Sunnybrook Health Sciences Centre
-
-
Quebec
-
Greenfield Park, Quebec, Canada, J4V 2H1
- CSSS Champlain-Charles Le Moyne
-
Montreal, Quebec, Canada, H3H 2R9
- The Research Institute of the McGill University Health Centre (MUHC)
-
Montreal, Quebec, Canada, H2W 1S6
- McGill University Department of Oncology
-
-
Saskatchewan
-
Regina, Saskatchewan, Canada, S4T 7T1
- Allan Blair Cancer Centre
-
Saskatoon, Saskatchewan, Canada, S7N 4H4
- Saskatoon Cancer Centre
-
-
-
-
Alabama
-
Birmingham, Alabama, Stati Uniti, 35233
- University of Alabama at Birmingham Cancer Center
-
Mobile, Alabama, Stati Uniti, 36688
- University of South Alabama Mitchell Cancer Institute
-
-
Arizona
-
Scottsdale, Arizona, Stati Uniti, 85259
- Mayo Clinic in Arizona
-
Tucson, Arizona, Stati Uniti, 85719
- Banner University Medical Center - Tucson
-
Tucson, Arizona, Stati Uniti, 85719
- University of Arizona Cancer Center-North Campus
-
-
Arkansas
-
Little Rock, Arkansas, Stati Uniti, 72205
- John L McClellan Memorial Veterans Hospital
-
-
California
-
Antioch, California, Stati Uniti, 94531
- Kaiser Permanente-Deer Valley Medical Center
-
Duarte, California, Stati Uniti, 91010
- City of Hope Comprehensive Cancer Center
-
Los Angeles, California, Stati Uniti, 90033
- USC / Norris Comprehensive Cancer Center
-
Oakland, California, Stati Uniti, 94611
- Kaiser Permanente-Oakland
-
Palo Alto, California, Stati Uniti, 94304
- Stanford Cancer Institute Palo Alto
-
Richmond, California, Stati Uniti, 94801
- Kaiser Permanente-Richmond
-
Sacramento, California, Stati Uniti, 95823
- Kaiser Permanente-South Sacramento
-
Sacramento, California, Stati Uniti, 95825
- Kaiser Permanente Sacramento Medical Center
-
San Francisco, California, Stati Uniti, 94115
- Kaiser Permanente-San Francisco
-
San Jose, California, Stati Uniti, 95119
- Kaiser Permanente-Santa Teresa-San Jose
-
San Rafael, California, Stati Uniti, 94903
- Kaiser Permanente-San Rafael
-
Santa Clara, California, Stati Uniti, 95051
- Kaiser Permanente Medical Center - Santa Clara
-
Santa Rosa, California, Stati Uniti, 95403
- Kaiser Permanente-Santa Rosa
-
Santa Rosa, California, Stati Uniti, 95403
- Sutter Pacific Medical Foundation
-
South San Francisco, California, Stati Uniti, 94080
- Kaiser Permanente-South San Francisco
-
Vallejo, California, Stati Uniti, 94589
- Kaiser Permanente-Vallejo
-
Walnut Creek, California, Stati Uniti, 94596
- Kaiser Permanente-Walnut Creek
-
-
Colorado
-
Aurora, Colorado, Stati Uniti, 80012
- The Medical Center of Aurora
-
Aurora, Colorado, Stati Uniti, 80045
- UCHealth University of Colorado Hospital
-
Boulder, Colorado, Stati Uniti, 80303
- Boulder Community Foothills Hospital
-
Colorado Springs, Colorado, Stati Uniti, 80907
- Penrose-Saint Francis Healthcare
-
Denver, Colorado, Stati Uniti, 80218
- Presbyterian - Saint Lukes Medical Center - Health One
-
Denver, Colorado, Stati Uniti, 80220
- Rose Medical Center
-
Denver, Colorado, Stati Uniti, 80218
- Rocky Mountain Cancer Centers-Midtown
-
Denver, Colorado, Stati Uniti, 80220
- Rocky Mountain Cancer Centers-Rose
-
Denver, Colorado, Stati Uniti, 80218
- Colorado Blood Cancer Institute
-
Denver, Colorado, Stati Uniti, 80222
- Western States Cancer Research NCORP
-
Denver, Colorado, Stati Uniti, 80218
- Saint Joseph Hospital - Cancer Centers of Colorado
-
Denver, Colorado, Stati Uniti, 80210
- AdventHealth Porter
-
Durango, Colorado, Stati Uniti, 81301
- Mercy Medical Center
-
Englewood, Colorado, Stati Uniti, 80113
- Mountain Blue Cancer Care Center - Swedish
-
Englewood, Colorado, Stati Uniti, 80113
- Swedish Medical Center
-
Fort Collins, Colorado, Stati Uniti, 80524
- Poudre Valley Hospital
-
Golden, Colorado, Stati Uniti, 80401
- Mountain Blue Cancer Care Center
-
Greeley, Colorado, Stati Uniti, 80631
- Banner North Colorado Medical Center
-
Greenwood Village, Colorado, Stati Uniti, 80111
- Rocky Mountain Cancer Centers-Greenwood Village
-
Lakewood, Colorado, Stati Uniti, 80228
- Rocky Mountain Cancer Centers-Lakewood
-
Lakewood, Colorado, Stati Uniti, 80228
- CommonSpirit Saint Anthony Hospital Cancer Center
-
Littleton, Colorado, Stati Uniti, 80122
- AdventHealth Littleton
-
Lone Tree, Colorado, Stati Uniti, 80124
- Sky Ridge Medical Center
-
Lone Tree, Colorado, Stati Uniti, 80124
- Rocky Mountain Cancer Centers-Sky Ridge
-
Longmont, Colorado, Stati Uniti, 80501
- Longmont United Hospital
-
Loveland, Colorado, Stati Uniti, 80539
- Banner North Colorado Medical Center - Loveland Campus
-
Parker, Colorado, Stati Uniti, 80138
- Rocky Mountain Cancer Centers-Parker
-
Parker, Colorado, Stati Uniti, 80138
- AdventHealth Parker
-
Pueblo, Colorado, Stati Uniti, 81004
- Saint Mary Corwin Medical Center
-
Wheat Ridge, Colorado, Stati Uniti, 80401
- Intermountain Health Lutheran Hospital
-
-
Connecticut
-
Farmington, Connecticut, Stati Uniti, 06030
- University of Connecticut
-
Hartford, Connecticut, Stati Uniti, 06105
- Smilow Cancer Hospital Care Center at Saint Francis
-
New Britain, Connecticut, Stati Uniti, 06050
- The Hospital of Central Connecticut
-
-
Delaware
-
Lewes, Delaware, Stati Uniti, 19958
- Beebe Medical Center
-
Newark, Delaware, Stati Uniti, 19718
- Christiana Care Health System-Christiana Hospital
-
-
District of Columbia
-
Washington D.C., District of Columbia, Stati Uniti, 20016
- Sibley Memorial Hospital
-
Washington D.C., District of Columbia, Stati Uniti, 20422
- Veterans Affairs Medical Center -Washington DC
-
-
Florida
-
Gainesville, Florida, Stati Uniti, 32610
- UF Health Cancer Institute - Gainesville
-
Jupiter, Florida, Stati Uniti, 33458
- Jupiter Medical Center
-
Miami Beach, Florida, Stati Uniti, 33140
- Mount Sinai Medical Center
-
Orlando, Florida, Stati Uniti, 32803
- AdventHealth Orlando
-
-
Georgia
-
Augusta, Georgia, Stati Uniti, 30912
- Augusta University Medical Center
-
-
Hawaii
-
Honolulu, Hawaii, Stati Uniti, 96813
- Hawaii Cancer Care Inc - Waterfront Plaza
-
Honolulu, Hawaii, Stati Uniti, 96813
- Straub Clinic and Hospital
-
Honolulu, Hawaii, Stati Uniti, 96813
- University of Hawaii Cancer Center
-
Honolulu, Hawaii, Stati Uniti, 96817
- Queen's Cancer Center - Kuakini
-
Honolulu, Hawaii, Stati Uniti, 96819
- Kaiser Permanente Moanalua Medical Center
-
-
Idaho
-
Boise, Idaho, Stati Uniti, 83706
- Saint Alphonsus Cancer Care Center-Boise
-
Post Falls, Idaho, Stati Uniti, 83854
- Kootenai Clinic Cancer Services - Post Falls
-
-
Illinois
-
Bloomington, Illinois, Stati Uniti, 61704
- Illinois CancerCare-Bloomington
-
Canton, Illinois, Stati Uniti, 61520
- Illinois CancerCare-Canton
-
Carthage, Illinois, Stati Uniti, 62321
- Illinois CancerCare-Carthage
-
Chicago, Illinois, Stati Uniti, 60611
- Northwestern University
-
Chicago, Illinois, Stati Uniti, 60637
- University of Chicago Comprehensive Cancer Center
-
Chicago, Illinois, Stati Uniti, 60612
- University of Illinois
-
Chicago, Illinois, Stati Uniti, 60611
- Hematology and Oncology Associates
-
Decatur, Illinois, Stati Uniti, 62526
- Decatur Memorial Hospital
-
Decatur, Illinois, Stati Uniti, 62526
- Heartland Cancer Research NCORP
-
Eureka, Illinois, Stati Uniti, 61530
- Illinois CancerCare-Eureka
-
Evanston, Illinois, Stati Uniti, 60201
- NorthShore University HealthSystem-Evanston Hospital
-
Galesburg, Illinois, Stati Uniti, 61401
- Illinois CancerCare-Galesburg
-
Havana, Illinois, Stati Uniti, 62644
- Illinois CancerCare-Havana
-
Kewanee, Illinois, Stati Uniti, 61443
- Illinois CancerCare-Kewanee Clinic
-
Macomb, Illinois, Stati Uniti, 61455
- Illinois CancerCare-Macomb
-
Maywood, Illinois, Stati Uniti, 60153
- Loyola University Medical Center
-
Moline, Illinois, Stati Uniti, 61265
- Trinity Medical Center
-
Monmouth, Illinois, Stati Uniti, 61462
- Illinois CancerCare-Monmouth
-
Normal, Illinois, Stati Uniti, 61761
- Illinois CancerCare-Community Cancer Center
-
Ottawa, Illinois, Stati Uniti, 61350
- Illinois CancerCare-Ottawa Clinic
-
Pekin, Illinois, Stati Uniti, 61554
- Illinois CancerCare-Pekin
-
Peoria, Illinois, Stati Uniti, 61615
- Illinois CancerCare-Peoria
-
Peru, Illinois, Stati Uniti, 61354
- Illinois CancerCare-Peru
-
Princeton, Illinois, Stati Uniti, 61356
- Illinois CancerCare-Princeton
-
Rockford, Illinois, Stati Uniti, 61104
- Swedish American Hospital
-
Rockford, Illinois, Stati Uniti, 61114
- UW Health Carbone Cancer Center Rockford
-
Springfield, Illinois, Stati Uniti, 62781
- Springfield Memorial Hospital
-
Urbana, Illinois, Stati Uniti, 61801
- Carle Cancer Center
-
-
Indiana
-
Merrillville, Indiana, Stati Uniti, 46410
- Premier Oncology Hematology Associates
-
-
Iowa
-
Ames, Iowa, Stati Uniti, 50010
- McFarland Clinic - Ames
-
Iowa City, Iowa, Stati Uniti, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
Sioux City, Iowa, Stati Uniti, 51101
- Siouxland Regional Cancer Center
-
Waterloo, Iowa, Stati Uniti, 50702
- MercyOne Waterloo Cancer Center
-
-
Kansas
-
Kansas City, Kansas, Stati Uniti, 66160
- University of Kansas Cancer Center
-
Prairie Village, Kansas, Stati Uniti, 66208
- Kansas City NCI Community Oncology Research Program
-
Topeka, Kansas, Stati Uniti, 66606
- Cotton O'Neil Cancer Center / Stormont Vail Health
-
-
Kentucky
-
Lexington, Kentucky, Stati Uniti, 40536
- University of Kentucky/Markey Cancer Center
-
-
Louisiana
-
Baton Rouge, Louisiana, Stati Uniti, 70809
- Ochsner Health Center-Summa
-
New Orleans, Louisiana, Stati Uniti, 70121
- Ochsner Medical Center Jefferson
-
Shreveport, Louisiana, Stati Uniti, 71103
- LSU Health Sciences Center at Shreveport
-
-
Maine
-
Bangor, Maine, Stati Uniti, 04401
- Eastern Maine Medical Center
-
-
Maryland
-
Baltimore, Maryland, Stati Uniti, 21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Elkton, Maryland, Stati Uniti, 21921
- Christiana Care - Union Hospital
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02215
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, Stati Uniti, 02114
- Massachusetts General Hospital Cancer Center
-
Brighton, Massachusetts, Stati Uniti, 02135
- Dana-Farber Cancer Institute at Boston Medical Center - Brighton
-
Springfield, Massachusetts, Stati Uniti, 01199
- Baystate Medical Center
-
Worcester, Massachusetts, Stati Uniti, 01655
- UMass Memorial Medical Center - University Campus
-
-
Michigan
-
Ann Arbor, Michigan, Stati Uniti, 48106
- Michigan Cancer Research Consortium NCORP
-
Ann Arbor, Michigan, Stati Uniti, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Battle Creek, Michigan, Stati Uniti, 49017
- Bronson Battle Creek
-
Detroit, Michigan, Stati Uniti, 48201
- Wayne State University/Karmanos Cancer Institute
-
Detroit, Michigan, Stati Uniti, 48236
- Henry Ford Health Saint John Hospital
-
Escanaba, Michigan, Stati Uniti, 49829
- OSF Saint Francis Hospital and Medical Group
-
Grand Rapids, Michigan, Stati Uniti, 49503
- Cancer Research Consortium of West Michigan NCORP
-
Grand Rapids, Michigan, Stati Uniti, 49503
- Trinity Health Grand Rapids Hospital
-
Grand Rapids, Michigan, Stati Uniti, 49503
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Kalamazoo, Michigan, Stati Uniti, 49007
- West Michigan Cancer Center
-
Muskegon, Michigan, Stati Uniti, 49444
- Trinity Health Muskegon Hospital
-
Port Huron, Michigan, Stati Uniti, 48060
- Lake Huron Medical Center
-
Reed City, Michigan, Stati Uniti, 49677
- Corewell Health Reed City Hospital
-
Traverse City, Michigan, Stati Uniti, 49684
- Munson Medical Center
-
Warren, Michigan, Stati Uniti, 48093
- Henry Ford Health Warren Hospital
-
-
Minnesota
-
Bemidji, Minnesota, Stati Uniti, 56601
- Sanford Joe Lueken Cancer Center
-
Burnsville, Minnesota, Stati Uniti, 55337
- Fairview Ridges Hospital
-
Coon Rapids, Minnesota, Stati Uniti, 55433
- Mercy Hospital
-
Duluth, Minnesota, Stati Uniti, 55805
- Essentia Health Cancer Center
-
Edina, Minnesota, Stati Uniti, 55435
- Fairview Southdale Hospital
-
Fridley, Minnesota, Stati Uniti, 55432
- Unity Hospital
-
Hutchinson, Minnesota, Stati Uniti, 55350
- Hutchinson Area Health Care
-
Maplewood, Minnesota, Stati Uniti, 55109
- Saint John's Hospital - Healtheast
-
Maplewood, Minnesota, Stati Uniti, 55109
- Minnesota Oncology Hematology PA-Maplewood
-
Minneapolis, Minnesota, Stati Uniti, 55415
- Hennepin County Medical Center
-
Minneapolis, Minnesota, Stati Uniti, 55407
- Abbott-Northwestern Hospital
-
Minneapolis, Minnesota, Stati Uniti, 55417
- Minneapolis VA Medical Center
-
Robbinsdale, Minnesota, Stati Uniti, 55422
- North Memorial Medical Health Center
-
Rochester, Minnesota, Stati Uniti, 55905
- Mayo Clinic in Rochester
-
Saint Cloud, Minnesota, Stati Uniti, 56303
- Coborn Cancer Center at Saint Cloud Hospital
-
Saint Louis Park, Minnesota, Stati Uniti, 55416
- Park Nicollet Clinic - Saint Louis Park
-
Saint Louis Park, Minnesota, Stati Uniti, 55416
- Metro Minnesota Community Oncology Research Consortium
-
Saint Paul, Minnesota, Stati Uniti, 55101
- Regions Hospital
-
Saint Paul, Minnesota, Stati Uniti, 55102
- United Hospital
-
Shakopee, Minnesota, Stati Uniti, 55379
- Saint Francis Regional Medical Center
-
Stillwater, Minnesota, Stati Uniti, 55082
- Lakeview Hospital
-
Waconia, Minnesota, Stati Uniti, 55387
- Ridgeview Medical Center
-
Willmar, Minnesota, Stati Uniti, 56201
- Rice Memorial Hospital
-
Woodbury, Minnesota, Stati Uniti, 55125
- Minnesota Oncology Hematology PA-Woodbury
-
-
Mississippi
-
Jackson, Mississippi, Stati Uniti, 39216
- University of Mississippi Medical Center
-
-
Missouri
-
Cape Girardeau, Missouri, Stati Uniti, 63703
- Saint Francis Medical Center
-
Columbia, Missouri, Stati Uniti, 65201
- Veterans Administration
-
Columbia, Missouri, Stati Uniti, 65212
- MU Health - University Hospital/Ellis Fischel Cancer Center
-
Kansas City, Missouri, Stati Uniti, 64111
- Saint Luke's Hospital of Kansas City
-
St Louis, Missouri, Stati Uniti, 63141
- Mercy Hospital Saint Louis
-
St Louis, Missouri, Stati Uniti, 63141
- Saint Louis-Cape Girardeau CCOP
-
-
Montana
-
Billings, Montana, Stati Uniti, 59101
- Billings Clinic Cancer Center
-
Bozeman, Montana, Stati Uniti, 59715
- Bozeman Health Deaconess Hospital
-
-
New Jersey
-
Camden, New Jersey, Stati Uniti, 08103
- Cooper Hospital University Medical Center
-
-
New Mexico
-
Albuquerque, New Mexico, Stati Uniti, 87106
- University of New Mexico Cancer Center
-
Albuquerque, New Mexico, Stati Uniti, 87110
- Presbyterian Kaseman Hospital
-
-
New York
-
Buffalo, New York, Stati Uniti, 14263
- Roswell Park Cancer Institute
-
Lake Success, New York, Stati Uniti, 11042
- Northwell Health/Center for Advanced Medicine
-
Manhasset, New York, Stati Uniti, 11030
- North Shore University Hospital
-
Mineola, New York, Stati Uniti, 11501
- NYU Langone Hospital - Long Island
-
New York, New York, Stati Uniti, 10065
- NYP/Weill Cornell Medical Center
-
Rochester, New York, Stati Uniti, 14642
- University of Rochester
-
The Bronx, New York, Stati Uniti, 10467
- Montefiore Medical Center - Moses Campus
-
The Bronx, New York, Stati Uniti, 10461
- Montefiore Medical Center-Weiler Hospital
-
-
North Carolina
-
Asheboro, North Carolina, Stati Uniti, 27203
- Randolph Hospital
-
Goldsboro, North Carolina, Stati Uniti, 27534
- Wayne Memorial Hospital
-
Greensboro, North Carolina, Stati Uniti, 27403
- Cone Health Cancer Center
-
Hendersonville, North Carolina, Stati Uniti, 28791
- Margaret R Pardee Memorial Hospital
-
Kinston, North Carolina, Stati Uniti, 28501
- ECU Health Oncology Kinston
-
Pinehurst, North Carolina, Stati Uniti, 28374
- FirstHealth of the Carolinas-Moore Regional Hospital
-
Reidsville, North Carolina, Stati Uniti, 27320
- Annie Penn Memorial Hospital
-
Statesville, North Carolina, Stati Uniti, 28677
- Iredell Memorial Hospital
-
Winston-Salem, North Carolina, Stati Uniti, 27104
- Southeast Clinical Oncology Research Consortium NCORP
-
-
North Dakota
-
Bismarck, North Dakota, Stati Uniti, 58501
- Sanford Bismarck Medical Center
-
Bismarck, North Dakota, Stati Uniti, 58501
- Mid Dakota Clinic
-
Fargo, North Dakota, Stati Uniti, 58122
- Sanford Roger Maris Cancer Center
-
Fargo, North Dakota, Stati Uniti, 58122
- Sanford Broadway Medical Center
-
-
Ohio
-
Beachwood, Ohio, Stati Uniti, 44122
- Cleveland Clinic Cancer Center Beachwood
-
Cincinnati, Ohio, Stati Uniti, 45219
- University of Cincinnati Cancer Center-UC Medical Center
-
Cleveland, Ohio, Stati Uniti, 44106
- Case Western Reserve University
-
Cleveland, Ohio, Stati Uniti, 44195
- Cleveland Clinic Foundation
-
Cleveland, Ohio, Stati Uniti, 44111
- Cleveland Clinic Cancer Center/Fairview Hospital
-
Columbus, Ohio, Stati Uniti, 43214
- Riverside Methodist Hospital
-
Columbus, Ohio, Stati Uniti, 43219
- The Mark H Zangmeister Center
-
Columbus, Ohio, Stati Uniti, 43222
- Mount Carmel Health Center West
-
Columbus, Ohio, Stati Uniti, 43215
- Columbus NCI Community Oncology Research Program
-
Dayton, Ohio, Stati Uniti, 45409
- Miami Valley Hospital
-
Independence, Ohio, Stati Uniti, 44131
- Cleveland Clinic Cancer Center Independence
-
Marietta, Ohio, Stati Uniti, 45750
- Marietta Memorial Hospital
-
Mayfield Heights, Ohio, Stati Uniti, 44124
- Hillcrest Hospital Cancer Center
-
Newark, Ohio, Stati Uniti, 43055
- Licking Memorial Hospital
-
Parma, Ohio, Stati Uniti, 44129
- University Hospitals Parma Medical Center
-
Sandusky, Ohio, Stati Uniti, 44870
- North Coast Cancer Care
-
Springfield, Ohio, Stati Uniti, 45504
- Springfield Regional Medical Center
-
Strongsville, Ohio, Stati Uniti, 44136
- Cleveland Clinic Cancer Center Strongsville
-
Sylvania, Ohio, Stati Uniti, 43560
- ProMedica Flower Hospital
-
Toledo, Ohio, Stati Uniti, 43614
- University of Toledo
-
Westerville, Ohio, Stati Uniti, 43081
- Saint Ann's Hospital
-
Wooster, Ohio, Stati Uniti, 44691
- Cleveland Clinic Wooster Family Health and Surgery Center
-
-
Oklahoma
-
Norman, Oklahoma, Stati Uniti, 73071
- Cancer Care Associates-Norman
-
Oklahoma City, Oklahoma, Stati Uniti, 73104
- University of Oklahoma Health Sciences Center
-
Oklahoma City, Oklahoma, Stati Uniti, 73120
- Mercy Hospital Oklahoma City
-
-
Oregon
-
Gresham, Oregon, Stati Uniti, 97030
- Legacy Mount Hood Medical Center
-
Milwaukie, Oregon, Stati Uniti, 97222
- Providence Milwaukie Hospital
-
Newberg, Oregon, Stati Uniti, 97132
- Providence Newberg Medical Center
-
Oregon City, Oregon, Stati Uniti, 97045
- Providence Willamette Falls Medical Center
-
Portland, Oregon, Stati Uniti, 97210
- Legacy Good Samaritan Hospital and Medical Center
-
Portland, Oregon, Stati Uniti, 97213
- Providence Portland Medical Center
-
Portland, Oregon, Stati Uniti, 97225
- Providence Saint Vincent Medical Center
-
-
Pennsylvania
-
Allentown, Pennsylvania, Stati Uniti, 18103
- Lehigh Valley Hospital-Cedar Crest
-
Carlisle, Pennsylvania, Stati Uniti, 17015
- Carlisle Regional Cancer Center
-
Danville, Pennsylvania, Stati Uniti, 17822
- Geisinger Medical Center
-
Doylestown, Pennsylvania, Stati Uniti, 18901
- Doylestown Hospital
-
Hazleton, Pennsylvania, Stati Uniti, 18201
- Geisinger Medical Center-Cancer Center Hazleton
-
Hershey, Pennsylvania, Stati Uniti, 17033-0850
- Penn State Milton S Hershey Medical Center
-
Pittsburgh, Pennsylvania, Stati Uniti, 15232
- UPMC Hillman Cancer Center
-
Sayre, Pennsylvania, Stati Uniti, 18840
- Guthrie Medical Group PC-Robert Packer Hospital
-
West Reading, Pennsylvania, Stati Uniti, 19611
- Reading Hospital
-
Wilkes-Barre, Pennsylvania, Stati Uniti, 18711
- Geisinger Wyoming Valley/Henry Cancer Center
-
-
South Carolina
-
Boiling Springs, South Carolina, Stati Uniti, 29316
- Prisma Health Cancer Institute - Spartanburg
-
Charleston, South Carolina, Stati Uniti, 29401
- Roper Hospital
-
Greenville, South Carolina, Stati Uniti, 29605
- Prisma Health Cancer Institute - Faris
-
Greenville, South Carolina, Stati Uniti, 29615
- Prisma Health Cancer Institute - Eastside
-
Greenville, South Carolina, Stati Uniti, 29605
- Prisma Health Cancer Institute - Butternut
-
Greenville, South Carolina, Stati Uniti, 29601
- Saint Francis Hospital
-
Greenville, South Carolina, Stati Uniti, 29605
- Prisma Health Greenville Memorial Hospital
-
Seneca, South Carolina, Stati Uniti, 29672
- Prisma Health Cancer Institute - Seneca
-
Spartanburg, South Carolina, Stati Uniti, 29303
- Spartanburg Medical Center
-
-
South Dakota
-
Rapid City, South Dakota, Stati Uniti, 57701
- Rapid City Regional Hospital
-
Sioux Falls, South Dakota, Stati Uniti, 57117-5134
- Sanford USD Medical Center - Sioux Falls
-
Sioux Falls, South Dakota, Stati Uniti, 57104
- Sanford Cancer Center Oncology Clinic
-
-
Tennessee
-
Knoxville, Tennessee, Stati Uniti, 37916
- Covenant Health Cancer Centers
-
Nashville, Tennessee, Stati Uniti, 37232
- Vanderbilt University/Ingram Cancer Center
-
-
Texas
-
Amarillo, Texas, Stati Uniti, 79106
- The Don and Sybil Harrington Cancer Center
-
Dallas, Texas, Stati Uniti, 75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
-
Utah
-
Salt Lake City, Utah, Stati Uniti, 84112
- Huntsman Cancer Institute/University of Utah
-
-
Virginia
-
Martinsville, Virginia, Stati Uniti, 24112
- Sovah Health Martinsville
-
-
Washington
-
Vancouver, Washington, Stati Uniti, 98664
- PeaceHealth Southwest Medical Center
-
-
West Virginia
-
Morgantown, West Virginia, Stati Uniti, 26506
- West Virginia University Healthcare
-
-
Wisconsin
-
Chippewa Falls, Wisconsin, Stati Uniti, 54729
- Marshfield Clinic-Chippewa Center
-
Eau Claire, Wisconsin, Stati Uniti, 54701
- HSHS Sacred Heart Hospital
-
Eau Claire, Wisconsin, Stati Uniti, 54701
- Marshfield Clinic Cancer Center at Sacred Heart
-
Green Bay, Wisconsin, Stati Uniti, 54311
- Aurora BayCare Medical Center
-
Green Bay, Wisconsin, Stati Uniti, 54301
- Saint Vincent Hospital Cancer Center Green Bay
-
Green Bay, Wisconsin, Stati Uniti, 54303
- Saint Vincent Hospital Cancer Center at Saint Mary's
-
Green Bay, Wisconsin, Stati Uniti, 54301-3526
- Green Bay Oncology at Saint Vincent Hospital
-
Janesville, Wisconsin, Stati Uniti, 53548
- Mercyhealth Hospital and Cancer Center - Janesville
-
La Crosse, Wisconsin, Stati Uniti, 54601
- Gundersen Lutheran Medical Center
-
Madison, Wisconsin, Stati Uniti, 53715
- SSM Health Dean Medical Group - South Madison Campus
-
Marinette, Wisconsin, Stati Uniti, 54143
- Aurora Bay Area Medical Group-Marinette
-
Marinette, Wisconsin, Stati Uniti, 54143
- Bay Area Medical Center
-
Marshfield, Wisconsin, Stati Uniti, 54449
- Marshfield Medical Center-Marshfield
-
Marshfield, Wisconsin, Stati Uniti, 54449
- Marshfield Medical Center
-
Milwaukee, Wisconsin, Stati Uniti, 53226
- Medical College of Wisconsin
-
Minocqua, Wisconsin, Stati Uniti, 54548
- Marshfield Medical Center - Minocqua
-
Oconomowoc, Wisconsin, Stati Uniti, 53066
- ProHealth Oconomowoc Memorial Hospital
-
Oconto Falls, Wisconsin, Stati Uniti, 54154
- Saint Vincent Hospital Cancer Center at Oconto Falls
-
Rhinelander, Wisconsin, Stati Uniti, 54501
- Aspirus Cancer Care-Rhinelander-James Beck Cancer Center
-
Rice Lake, Wisconsin, Stati Uniti, 54868
- Marshfield Medical Center-Rice Lake
-
Stevens Point, Wisconsin, Stati Uniti, 54481
- Aspirus Cancer Care - Stevens Point
-
Summit, Wisconsin, Stati Uniti, 53066
- Aurora Medical Center in Summit
-
Waukesha, Wisconsin, Stati Uniti, 53188
- ProHealth Waukesha Memorial Hospital
-
Wauwatosa, Wisconsin, Stati Uniti, 53226
- Aurora Cancer Care-Milwaukee West
-
Weston, Wisconsin, Stati Uniti, 54476
- Marshfield Medical Center - Weston
-
Wisconsin Rapids, Wisconsin, Stati Uniti, 54494
- Marshfield Clinic - Wisconsin Rapids Center
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
Patients must have morphologically confirmed diagnosis of myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) based on one of the following:
-
French-American-British (FAB) classifications:
- Refractory anemia with excess blasts (RAEB - defined as having 5-20% myeloblasts in the bone marrow)
- Chronic myelomonocytic leukemia (CMML) with 10-19% myeloblasts in the bone marrow and/or 5-19% blasts in the blood
-
World Health Organization (WHO) classifications:
- Refractory anemia with excess blasts-1 (RAEB-1 - defined as having 5-9% myeloblasts in the bone marrow)
- Refractory anemia with excess blasts-2 (RAEB-2 - defined as having 10-19% myeloblasts in the bone marrow and/or 5-19% blasts in the blood)
- Chronic myelomonocytic leukemia-1 (CMML-1 - defined as having < 10% myeloblasts in the bone marrow and/or < 5% blasts in the blood)
- Chronic myelomonocytic leukemia-2 (CMML-2 - defined as having 10-19% myeloblasts in the bone marrow and/or 5-19% blasts in the blood) OR
-
International prognostic score (IPSS) of intermediate 2 (1.5-2.0 points) or high (>= 2.5 points); a score of intermediate 1 (0.5-1.0 points) is only allowable in the setting of >= 5% myeloblasts
-
NOTE: Patients with acute myeloid leukemia (AML) are not eligible
-
Procedures to obtain specimens for establishing baseline disease must be done within 30 days prior to registration
-
-
Patients must not have received lenalidomide, azacitidine, vorinostat, or decitabine as treatment previously; any hematopoietic growth factors must be stopped for at least 14 days prior to registration; patients may have received low-dose cytarabine for MDS treatment previously, but they must have discontinued its use for at least 28 days prior to registration; patients may have received prior hydroxyurea per CMML treatment previously, but they must have discontinued its use for at least 7 days prior to registration; these patients will not be eligible if white blood cell (WBC) > 30,000/mm^3
-
Patients must not have received radiation therapy, chemotherapy, or cytotoxic therapy to treat conditions other than MDS within 12 months prior to registration
-
Patients must not have undergone prior allogeneic stem cell or bone marrow transplantation at any time; patients that have undergone an autologous stem cell transplant are eligible
-
Patients must not have used or be using histone deacetylase (HDAC) inhibitor agents for anticancer treatment
-
Patients may not have received agents such as valproic acid for epilepsy within 30 days prior to registration
-
Patients must have Zubrod performance status of 0-2
-
Patients must not have any pre-existing neurotoxicity/neuropathy of >= grade 2 according to the National Cancer Institute (NCI) Common Toxicity Criteria version 4.0, or prior >= grade 3 allergic reaction/hypersensitivity or rash to thalidomide, that has not resolved to < grade 2
-
Patients must not have any serious medical condition, laboratory abnormality, or psychiatric illness that, in the view of the treating physician, would place the participant at an unacceptable risk if he or she were to participate in the study or would prevent that person from giving informed consent
-
Patients must not have history of thromboembolic event or other condition requiring current use of anticoagulation with Coumadin (warfarin) or low molecular-weight heparin
-
Patients must not have known or suspected hypersensitivity to mannitol
-
Patients must receive a 12-lead electrocardiogram (EKG), chest x-ray or computed tomography (CT) scan, serum creatinine, complete metabolic panel including serum glutamic oxaloacetic transaminase (SGOT) or serum glutamate pyruvate transaminase (SGPT), electrolytes, and bilirubin testing within 28 days prior to registration in order to establish baseline measurements; questions regarding patient safety in regards to results of these tests should be directed to the study chair
-
Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 10 - 14 days prior to registration; FCBP must agree to have a second pregnancy test within 24 hours prior to starting cycle 1 if randomized to receive lenalidomide
- Further, patients commit to the following if they are randomized to receive lenalidomide: FCBP must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control: one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before starting lenalidomide; FCBP must also agree to ongoing pregnancy testing; men must agree to use a latex condom during sexual contact with a FCBP, even if they have had a successful vasectomy; a FCBP is a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months); all patients must be counseled by a trained counselor every 28 days about pregnancy precautions and risks of fetal exposure
- NOTE: Patients not randomized to receive lenalidomide will not be required to undergo serial pregnancy testing or lenalidomide counseling after registration
-
No prior malignancy is allowed except for adequately treated basal cell (or squamous cell) skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for three years
-
Cytogenetics requirements:
- Southwestern Oncology Group (SWOG) (and other sites not affiliated with Alliance or Eastern Cooperative Oncology Group [ECOG]-American College of Radiology Imaging Network [ACRIN]): Pretreatment cytogenetics must be performed on all patients; collection of pretreatment specimens must be completed within 30 days prior to registration to S1117; specimens must be submitted to the site's preferred Clinical Laboratory Improvement Amendments (CLIA)-approved cytogenetics laboratory; reports of the results must be submitted as described; note that cytogenetics are required at other timepoints; NOTE: National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) sites may submit specimens to College of American Pathologists (CAP) or Ontario Laboratory Accreditation (OLA)-approved laboratories providing the lab is licensed to perform fluorescent in situ hybridization (FISH) analysis
- Alliance: Alliance patients must enroll on Cancer and Leukemia Group B (CALGB) 8461, the cytogenetics protocol; CALGB 8461 provides sample procurement and submission instructions to Alliance-approved institutional cytogeneticists; note that cytogenetics are required at other timepoints
- ECOG-ACRIN: Pretreatment cytogenetics must be performed on all patients; collection of pretreatment specimens must be completed within 30 days prior to registration to S1117; specimens must be submitted to the site's preferred CLIA-approved cytogenetics laboratory; karyotypes and reports must be submitted for review to the Mayo Clinic Cytogenetics Laboratory in Rochester; note that cytogenetics testing is required at other timepoints
-
Banking requirements:
- SWOG, Alliance and ECOG-ACRIN (and other sites not affiliated with NCIC CTG): Patients must be offered participation in specimen banking; with patient consent, specimens must be submitted as outlined
- Alliance: (Temporarily Closed 2/28/14): As of February 28, 2014, CALGB 9665 has been temporarily closed, so Alliance patients under consideration for S1117 are NOT to be registered to CALGB 9665 and no specimens for patients enrolled after February 28, 2014 are to be submitted via this ancillary study; these patients should submit specimens per SWOG instructions; patients already enrolled on CALGB 9665 should continue to submit specimens per instructions in CALGB 9665
- NCIC CTG: NCIC CTG patients must be offered participation in specimen submission and banking; with patient consent, specimens must be submitted as outlined
-
All patients or their legally authorized representative must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
-
As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Arm I (azacitidine and lenalidomide)
Patients receive azacitidine SC or IV on days 1-7 or days 1-5 and 8-9, and lenalidomide PO QD on days 1-21. Courses repeat every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity. |
Correlative studies Given PO
Altri nomi:
Given SC or IV
Altri nomi:
|
|
Sperimentale: Arm II (azacitidine)
Patients receive azacitidine as in Arm I. Courses repeat every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity. |
Correlative studies Given SC or IV
Altri nomi:
|
|
Sperimentale: Arm III (azacitidine and vorinostat)
Patients receive azacitidine as in Arm I and vorinostat PO BID on days 3-9. Courses repeat every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity. |
Correlative studies Given SC or IV
Altri nomi:
Given PO
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Response Rate (Phase II)
Lasso di tempo: Up to 5 years
|
A response is any of complete hematological remission, partial remission, or hematologic improvement. |
Up to 5 years
|
|
Overall Survival (Phase III)
Lasso di tempo: Up to 5 years
|
OS is calculated for all patients from the date of initial registration to date of death due to any cause. The follow-up for patients last known to be alive is censored at the date of last contact. Stratified Cox regression models will be used to compare OS of the combination arm selected in the Phase II portion of the trial to OS of the single-agent azacitidine arm. |
Up to 5 years
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Relapse-free Survival
Lasso di tempo: Up to 5 years
|
RFS is calculated for patients who have achieved a response. RFS will be measured from the date of response to the date of first documentation of relapse from response (as defined in the primary objective), or death due to any cause. The follow-up for patients last known to be alive and without report of relapse is censored at the date of last contact. RFS will be estimated for each of the three arms using the Kaplan-Meier method. |
Up to 5 years
|
|
Overall Survival
Lasso di tempo: Up to 5 years
|
OS is calculated for all patients from the date of initial registration to date of death due to any cause. The follow- up for patients last known to be alive is censored at the date of last contact. OS will be estimated for each of the three arms using the Kaplan-Meier method. |
Up to 5 years
|
|
Pre-study Cytogenetic Abnormalities
Lasso di tempo: Up to 5 years
|
Cytogenetic risk group is used to identify cytogenetic abnormalities. |
Up to 5 years
|
|
Toxicity Rate
Lasso di tempo: Up to 5 years
|
Adverse events that are possibly, probably or definitely related to study drug are reported. |
Up to 5 years
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Mikkael A Sekeres, SWOG Cancer Research Network
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stimato)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Processi patologici
- Neoplasie
- Malattia cronica
- Attributi della malattia
- Malattie genetiche, congenite
- Neoplasie per tipo istologico
- Malattie ematologiche
- Leucemia, mieloide
- Malattie mielodisplastiche-mieloproliferative
- Malattie del midollo osseo
- Anemia
- Leucemia
- Anemia, refrattaria
- Malattie e anomalie congenite, ereditarie e neonatali
- Condizioni patologiche, segni e sintomi
- Malattie emiche e linfatiche
- Carenza di GATA2
- Leucemia, mielomonocitica, cronica
- Sindromi mielodisplastiche
- Anemia, refrattaria, con eccesso di blasti
- Prodotti chimici organici
- Composti eterociclici, 1-anello
- Composti eterociclici
- Composti eterociclici, 2 anelli
- Composti eterociclici, anello fuso
- Acidi nucleici, nucleotidi e nucleosidi
- Acidi carbossilici
- Idrossi acidi
- Anilides
- Amides
- Composti di anilina
- Ammine
- Piperidine
- Citidina
- Nucleosidi di pirimidina
- Pirimidine
- Composti aza
- Nucleosidi
- Ribonucleosidi
- Ftalimides
- Acidi ftalici
- Acidi, carbociclico
- Piperidoni
- Isoindoli
- Acidi idrossamici
- Idrossilammine
- Lenalidomide
- Vorinostat
- Azacitidina
Altri numeri di identificazione dello studio
- NCI-2012-00242
- U10CA032102 (Sovvenzione/contratto NIH degli Stati Uniti)
- U10CA180888 (Sovvenzione/contratto NIH degli Stati Uniti)
- NCI-2012-00242 (Identificatore di registro: CTRP (Clinical Trial Reporting Program))
- CDR0000723909
- SWOG-S1117
- S1117 (Altro identificatore: CTEP)
- S1117 (Altro identificatore: SWOG)
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .